L3VLUP
ProSign in

ABCL · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ABCLJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ABCL
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterABCLJNJ
Q3 2020none listed holders, n.a.30 holders, $26.2bn
Q4 20204 holders, $960m32 holders, $26.6bn
Q1 20214 holders, $837m31 holders, $25.3bn
Q2 20213 holders, $364m37 holders, $25.6bn
Q3 20213 holders, $470m40 holders, $24.1bn
Q4 20213 holders, $376m33 holders, $25.2bn
Q1 20223 holders, $287m35 holders, $28.2bn
Q2 20225 holders, $326m33 holders, $26.9bn
Q3 20227 holders, $270m36 holders, $25.4bn
Q4 20223 holders, $294m35 holders, $27.6bn
Q1 20234 holders, $221m42 holders, $24.5bn
Q2 20234 holders, $226m38 holders, $25.0bn
Q3 20233 holders, $160m37 holders, $18.9bn
Q4 20233 holders, $186m31 holders, $19.0bn
Q1 20243 holders, $144m32 holders, $19.7bn
Q2 20243 holders, $81m35 holders, $20.4bn
Q3 20241 holders, $34m28 holders, $22.3bn
Q4 20242 holders, $59m37 holders, $20.4bn
Q1 20252 holders, $55m32 holders, $20.5bn
Q2 20253 holders, $95m31 holders, $18.4bn
Q3 20255 holders, $147m32 holders, $23.7bn
Q4 20253 holders, $63m29 holders, $27.8bn
Q1 20261 holders, $47m34 holders, $35.6bn
Q2 20262 holders, $189m33 holders, $39.1bn
ABCL

Abcellera Biologics Inc

Holders
2
Reported value
$189m
Buyers
12
Sellers
13

Breadth -1 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
33
Reported value
$39.1bn
Buyers
18
Sellers
21

Breadth -3 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2026

Among the 34 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ABCL (1)

Two Sigma Investments LP

Only JNJ (32)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Farallon Capital Management LLC, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Holocene Advisors LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, and 7 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →